Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Leukemia
Lung Cancers
Melanoma
Prostate Cancer
Urology
CLL
Precision Medicine
Supportive Care
More...
Giants Cancer Care

Dr. Bradley Discusses Moxetumomab Pasudotox

Edward Bradley, MD
Published Online: Tuesday, July 30, 2013
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), discusses the development of moxetumomab pasudotox.

Moxetumomab pasudotox is a monoclonal antibody made up of an antibody directed at CD22 and Pseudomonas exotoxin. The agent binds to CD22 on the surface of the tumor cell and is incorporated into the cell before the Pseudomonas exotoxin metabolizes, is released, and kills the cell.

In a phase I trial, patients with hairy cell leukemia who had failed previous therapy saw over 90% response rate, with over half being complete responses. Bradley said that the durability of the responses was most striking and that moxetumomab pasudotox was well-tolerated.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
 
$auto_registration$